| Old Articles: <Older 4501-4510 Newer> |
|---|
 |
The Motley Fool
January 16, 2008
Brian Lawler |
More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note.   |
The Motley Fool
January 16, 2008
Brian Lawler |
Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note. |
The Motley Fool
January 16, 2008
Brian Orelli |
Headache Almost Over for Pozen The drug is safe; hopefully that's all the FDA wanted to know. |
Chemistry World
January 15, 2008
Hepeng Jia |
Huge Project to Boost Chinese Drug Development The Chinese government has agreed a multi-billion drug development funding program to boost innovation in its generics-dominated pharmaceutical sector. |
The Motley Fool
January 15, 2008
Brian Orelli |
Fewer Generics in Fido's Future TEVA considers selling its small animal-health business. |
The Motley Fool
January 15, 2008
Brian Lawler |
Gauging Genentech Genentech releases its fourth-quarter results; in which revenues were up and adjusted earnings per share gained. |
The Motley Fool
January 15, 2008
Brian Orelli |
Ideal Results From Schering A post-marketing clinical trial from Schering on its hepatitis C virus treatment Pegintron yields better results for the company, although not without some controversy. Investors, take note. |
The Motley Fool
January 15, 2008
Brian Orelli |
No Enhance-ment From Zetia Merck and Schering report bad news, but how much will it affect sales? Investors, take note. |
The Motley Fool
January 14, 2008
Brian Lawler |
Score One for Dendreon and Disclosure A prestigious journal supports Dendreon's potential prostate cancer treatment, and makes a compelling case for more FDA disclosure. |
The Motley Fool
January 14, 2008
Brian Lawler |
Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008. |
| <Older 4501-4510 Newer> Return to current articles. |
